Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Blood
Reexamination Certificate
2008-09-26
2010-11-02
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Blood
C514S002600, C530S350000
Reexamination Certificate
active
07824712
ABSTRACT:
Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo.
REFERENCES:
patent: 4554101 (1985-11-01), Hopp
patent: 5284656 (1994-02-01), Platz et al.
patent: 5320840 (1994-06-01), Camble et al.
patent: 5399345 (1995-03-01), Schumacher et al.
patent: 5416195 (1995-05-01), Camble et al.
patent: 5422248 (1995-06-01), Smith et al.
patent: 5766944 (1998-06-01), Ruiz
patent: 5891429 (1999-04-01), Clark et al.
patent: 5895646 (1999-04-01), Wang
patent: 5908763 (1999-06-01), Clark et al.
patent: 5919757 (1999-07-01), Michaelis et al.
patent: 5981551 (1999-11-01), Luengo et al.
patent: 6150085 (2000-11-01), Hess et al.
patent: 6162427 (2000-12-01), Baumann et al.
patent: 6166183 (2000-12-01), Ishikawa et al.
patent: 6261550 (2001-07-01), Osslund
patent: 6565841 (2003-05-01), Niven et al.
patent: 6646110 (2003-11-01), Nissen et al.
patent: 2001/0009922 (2001-07-01), Faller
Cavallaro et al., Bone Marr. Trans. 25: 85-89, 2000.
Scarpellini, et al., “Effectiveness of GM-CSF 1 in the treatment of habitual abortion in a controlled study”, Fertility and Sterility, vol. 80, No Suppl. 3, Sep. 2003, pp. S288, XP009117277 & 59th Annual Meeting of the American Society for Reproductive Medicine; San Antonio, Texas, USA; Oct. 11-15, 2003.
Calhoun et al: “A randomized pilot trial of administration of granulocyte colony-stimulating factor to women before preterm delivery” AmericanJournal of Obstetrics & Gynecology, Mosby, St. Louis, MO, US, vol. 179, No. 3, Sep. 1998, pp. 766-771, XP005691470, p. 768, col. 2, last paragraph.
Clark, et al., “Prevention of Spontaneous Abortion in DBA/2-Mated CBA/J Mice by GM-CSF Involves CD8<+> T Cell-Dependent Suppression of Natural Effector Cell Cytotoxicity against Trophoblast Target Cells” Cellular Immunology, Academic Press, San Diego, CA, US, vol. 154, No. 1, Mar. 1994, pp. 143-152, XP024000154 [retrieved on Mar. 1, 1994].
Perricone, et al., “GM-CSF and pregnancy: evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment.” American Journal of Reproductive Immunology, (New York, New York 1989) Sep. 2003, vol. 50, No. 3, pp. 232-237, XP002528902.
Duan, “Production of granulocyte colony stimulating factor in decidual tissue and its significance in pregnancy” Osaka Medical Journal, Osaka, JP, vol. 36, No. 2,Nov. 1990, pp. 81-97, XP009117224, p. 81-82.
Medlock, “Granulocyte colony-stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis.” BLOOD Feb. 15, 1993, vol. 81, No. 4, pp. 916-922, XP002528903.
Supplementary European Search Report (PCT/US2004035468), dated Jun. 6, 2009.
Mori, T., et al., “Immunomolecular mechanisms in mammalian Implantation”, Endocrine Journal, vol. 41 SUPP, pp. s17-s31 (1994).
International Search Report (International Application No. PCT/US04/35468 filed Oct. 25, 2004).
Arpaci, F., et al., “A Successful and Simplified Filgrastim Primed Single Apheresis Method Without Large Volume Apheresis for Peripheral Blood Stem Cell Collection,” Jpn. J. Clin. Oncol., vol. 30, No. 3, pp. 153-158 (2000).
Berenson, R.J., et al., “Transplantation of CD34+ Hematopoietic Progenitor Cells,” Cancer Investigation, vol. 14, No. 6, pp. 589-596 (1996).
Bueno, J.T., et al, “Endoscopic placement of direct percutaneous jejunostomy tubes in patients with complications after esophagectomy,” Gastrointestinal Endoscopy, vol. 57, No. 4, pp. 536-540 (2003).
Cameo, M. et al. “Similar embryotoxic effects of sera from infertile patients and exogenous interferon-γ on long-term in-vitro development of mouse embryos,” Human Reproduction, vol. 14, No. 4, pp. 959-963 (1999).
Chaouat, G., et al., “Implantation: can immunological parameters of implantation failure be of interest for pre-eclampsia?”, Journal of Reproductive Immunology, vol. 59, pp. 205-217 (2003).
Dreger, P., et al., “G-CSF-mobilized peripheral blood progenitor cells for allogenic transplantation: safety, kinetics of mobilization, and composition of the graft,” British Journal of Haematology, vol. 87, pp. 609-613 (1994).
Dudrick, S.J., et al., “Total Parenteral Nutrition: Techniques, Complications, and Prevention,” Surgical Technology International VII, pp. 174-184 (1998).
Krishnan, L., et al., “T Helper 1 Response Against Leishmania major in Pregnant C57BL/6 Mice Increases Implantation Failure and Fetal Resorptions,” The Journal of Immunology, vol. 156, pp. 653-662 (1996).
Kwak-Kim, J.Y.H., et al., “Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF,” Human Reproduction, vol. 18, No. 4, pp. 767-773 (2003).
Link, H., et al., “CD34 Positive Blood Cells for Allogeneic Progenitor and Stem Cell Transplantation,” Leukemia and Lymphoma, vol. 26, pp. 451-465 (1997) [current as of Jul. 22, 2008].
Mauri, C., et al., “Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis,” Eur. J. Immunol., vol. 26, pp. 1151-1518 (1996).
Mohandas, K.M., et al., “Total parenteral nutrition,” The National Medical Journal of India, vol. 16, No. 1, pp. 29-33 (2003).
Moverare, R., et al., “Study of the Th1/Th2 balance, including IL-10 production, in cultures of peripheral blood mononuclear cells from birch-pollen-allergic patients,” Allergy, vol. 55, pp. 171-175 (2000).
Oksenberg, J.R., et al., “In Vitro Suppression of Murine Blastocysts Growth by Sera From Women With Reproductive Disorders,” American Journal of Reproductive Immunology and Microbiology, vol. 11, pp. 118-124 (1986).
Papadimitriou, C.A., et al., “Non-Cryopreserved Peripheral Blood Progenitor Cells Collected by a Single Very Large-Volume Leukapheresis: A Simplified and Effective Procedure for Support of High-Dose Chemotherapy,” Journal of Clinical Apheresis, vol. 15, pp. 236-241 (2000).
Raghupathy, R., et al., “Maternal Th1- and Th2-Type Reactivity to Placental Antigens in Normal Human Pregnancy and Unexplained Recurrent Spontaneous Abortions,” Cellular Immunology, vol. 196, pp. 122-130 (1999).
Raziuddin, S., et al. “Divergent Cytokine Production Profile in Behçet's Disease. Altered Th1/Th2 Cell Cytokine Pattern,” The Journal of Rheumatology, vol. 25, No. 2, pp. 329-333 (1998).
Roussev, R.G., et al., “Validation of an Embryotoxicity Assay,” American Journal of Reproductive Immunology, vol. 33, pp. 171-175 (1995).
Scarpellini, F., et al., “Effectiveness of GM-CSF 1 in the Treatment of Habitual Abortion in a Controlled Study,” American Journal of Reproductive Immunology (Abstracts), vol. 51, pp. 433-434 (2004).
Schust, D.J., et al., “Correlation of Serum Cytokine and Adhesion Molecule Determinations With Pregnancy Outcome,” J. Soc. Gynecol. Invest., vol. 3, No. 5, pp. 259-261, Sep./Oct. (1996).
Shike, M., et al., “Direct percutaneous endoscopic jejunostomies for enteral feeding,” Gastrointestinal Endoscopy, vol. 44, No. 5, pp. 536-540 (1996).
Thomason, E.J., et al., “Prevalence of Embryotoxic Factor in Sera From Women With Unexplained Recurrent Abortion,” American Journal of Reproductive Immunology, vol. 34, pp. 338-341 (1995).
Vogel, W., et al., “Clinical Applications of CD34+ Peripheral Blood Progenitor Cells (PBPC),” Stem Cells 2000, vol. 18, pp. 87-92 (2000).
Yabuki, A., et al., “Giant Lysosomes in the Rena
Andrews & Kurth LLP
Chandra Gyan
Landsman Robert
Nora Therapeutics, Inc.
Wang Ping
LandOfFree
Method for reducing the likelihood of implantation failure... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing the likelihood of implantation failure..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing the likelihood of implantation failure... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247845